MedTrace Logo

Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of MBX-2982 Administered Daily for 4 Weeks as Monotherapy in Patients With Type 2 Diabetes

NCT01035879 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2015-04-17

No results posted yet for this study

Summary

To define the relative efficacy, safety and tolerability profiles of oral daily MBX-2982 at three different daily doses vs. placebo and sitagliptin 100 mg when administered for up to 4 weeks in patients that are treatment-naive or taking a single anti-diabetic medication (non-TZD, non-injectable).

Conditions

Interventions

DRUG

MBX-2982

tablets and capsule once daily

DRUG

MBX-2982

tablets and capsule once daily

DRUG

MBX-2982

tablets and capsule once daily

DRUG

Sitagliptin

tablets and capsule once daily

DRUG

placebo

tablets and capsule once daily

Sponsors & Collaborators

Principal Investigators

  • Brian Roberts, MD · Metabolex, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2010-08-31
Completion
2010-08-31

Countries

  • United States
  • Georgia
  • India

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01035879 on ClinicalTrials.gov